ID

34806

Beschreibung

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF); ODM derived from: https://clinicaltrials.gov/show/NCT02240667

Link

https://clinicaltrials.gov/show/NCT02240667

Stichworte

Versionen (1)
  1. 30.01.19 30.01.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

30. Januar 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Atrial Fibrillation NCT02240667

Englisch

Eligibility Atrial Fibrillation NCT02240667

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
newly prescribed treatment with pradaxa® (dabigatranetexilat)/vitamine k antagonist (vka) in indication stroke prevention in non-valvular atrial fibrillation (af), respecting indication and contraindications as described in the respective summary of product characteristics for pradaxa®110 mg resp. 150 mg capsules, resp. vka.
Beschreibung

Pradaxa prescribed | dabigatran etexilate | Vitamin K antagonists | Stroke prevention | Atrial Fibrillation | Heart Valve Involvement Absent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C2940579
UMLS CUI [1,2]
C0278329
UMLS CUI [2]
C1571583
UMLS CUI [3]
C3653316
UMLS CUI [4]
C1277289
UMLS CUI [5]
C0004238
UMLS CUI [6,1]
C0018826
UMLS CUI [6,2]
C1314939
UMLS CUI [6,3]
C0332197
patients suitable for therapy with pradaxa as well as with vka.
Beschreibung

Patients Appropriate Pradaxa | Patients Appropriate Vitamin K antagonists

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C1548787
UMLS CUI [1,3]
C2940579
UMLS CUI [2,1]
C0030705
UMLS CUI [2,2]
C1548787
UMLS CUI [2,3]
C3653316
treatment with dabigatranetexilat resp. vka follows summary of product characteristics.
Beschreibung

dabigatran etexilate | Vitamin K antagonists

Datentyp

boolean

Alias
UMLS CUI [1]
C1571583
UMLS CUI [2]
C3653316
the usual routine in diagnostics and treatment will not be modified.
Beschreibung

Routine Diagnostic unchanged | Routine Treatment unchanged

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0205547
UMLS CUI [1,2]
C0011900
UMLS CUI [1,3]
C0442739
UMLS CUI [2,1]
C0205547
UMLS CUI [2,2]
C0087111
UMLS CUI [2,3]
C0442739
only patients will be documented qualifying for vka-therapy as well as for dabigatranetexilat acc. to pradaxa® resp. vka summary of product characteristics.
Beschreibung

Qualification Vitamin K antagonists | Qualification Dabigatran etexilate

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1709790
UMLS CUI [1,2]
C3653316
UMLS CUI [2,1]
C1709790
UMLS CUI [2,2]
C1571583
written informed consent before inclusion.
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with general or special contraindications acc. to summary of product characteristics.
Beschreibung

Medical contraindication General | Medical contraindication Special

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0205246
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0205555
patients participating at the same time or within the last 30 days in another non-interventional study (nis) or interventional clinical trial.
Beschreibung

Study Subject Participation Status | Clinical Trial Without Interventional procedure | Interventional Study

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C0008976
UMLS CUI [2,2]
C0332288
UMLS CUI [2,3]
C0184661
UMLS CUI [3]
C3274035
patients needing anticoagulative treatment for indications other than non-valvular atrial fibrillation.
Beschreibung

Patient need for Anticoagulation Therapy | Exception Indication Atrial Fibrillation

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0686904
UMLS CUI [1,2]
C0003281
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C3146298
UMLS CUI [2,3]
C0004238
pregnancy or breastfeeding
Beschreibung

Pregnancy | Breast Feeding

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Atrial Fibrillation NCT02240667

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Pradaxa prescribed | dabigatran etexilate | Vitamin K antagonists | Stroke prevention | Atrial Fibrillation | Heart Valve Involvement Absent
Item
newly prescribed treatment with pradaxa® (dabigatranetexilat)/vitamine k antagonist (vka) in indication stroke prevention in non-valvular atrial fibrillation (af), respecting indication and contraindications as described in the respective summary of product characteristics for pradaxa®110 mg resp. 150 mg capsules, resp. vka.
boolean
C2940579 (UMLS CUI [1,1])
C0278329 (UMLS CUI [1,2])
C1571583 (UMLS CUI [2])
C3653316 (UMLS CUI [3])
C1277289 (UMLS CUI [4])
C0004238 (UMLS CUI [5])
C0018826 (UMLS CUI [6,1])
C1314939 (UMLS CUI [6,2])
C0332197 (UMLS CUI [6,3])
Patients Appropriate Pradaxa | Patients Appropriate Vitamin K antagonists
Item
patients suitable for therapy with pradaxa as well as with vka.
boolean
C0030705 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C2940579 (UMLS CUI [1,3])
C0030705 (UMLS CUI [2,1])
C1548787 (UMLS CUI [2,2])
C3653316 (UMLS CUI [2,3])
dabigatran etexilate | Vitamin K antagonists
Item
treatment with dabigatranetexilat resp. vka follows summary of product characteristics.
boolean
C1571583 (UMLS CUI [1])
C3653316 (UMLS CUI [2])
Routine Diagnostic unchanged | Routine Treatment unchanged
Item
the usual routine in diagnostics and treatment will not be modified.
boolean
C0205547 (UMLS CUI [1,1])
C0011900 (UMLS CUI [1,2])
C0442739 (UMLS CUI [1,3])
C0205547 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C0442739 (UMLS CUI [2,3])
Qualification Vitamin K antagonists | Qualification Dabigatran etexilate
Item
only patients will be documented qualifying for vka-therapy as well as for dabigatranetexilat acc. to pradaxa® resp. vka summary of product characteristics.
boolean
C1709790 (UMLS CUI [1,1])
C3653316 (UMLS CUI [1,2])
C1709790 (UMLS CUI [2,1])
C1571583 (UMLS CUI [2,2])
Informed Consent
Item
written informed consent before inclusion.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Medical contraindication General | Medical contraindication Special
Item
patients with general or special contraindications acc. to summary of product characteristics.
boolean
C1301624 (UMLS CUI [1,1])
C0205246 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0205555 (UMLS CUI [2,2])
Study Subject Participation Status | Clinical Trial Without Interventional procedure | Interventional Study
Item
patients participating at the same time or within the last 30 days in another non-interventional study (nis) or interventional clinical trial.
boolean
C2348568 (UMLS CUI [1])
C0008976 (UMLS CUI [2,1])
C0332288 (UMLS CUI [2,2])
C0184661 (UMLS CUI [2,3])
C3274035 (UMLS CUI [3])
Patient need for Anticoagulation Therapy | Exception Indication Atrial Fibrillation
Item
patients needing anticoagulative treatment for indications other than non-valvular atrial fibrillation.
boolean
C0686904 (UMLS CUI [1,1])
C0003281 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C3146298 (UMLS CUI [2,2])
C0004238 (UMLS CUI [2,3])
Pregnancy | Breast Feeding
Item
pregnancy or breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video